Cargando…

APOL1 Renal-Risk Variants Do Not Associate With Incident Cardiovascular Disease or Mortality in the Systolic Blood Pressure Intervention Trial

INTRODUCTION: Relationships between apolipoprotein L1 gene (APOL1) renal-risk variants (RRVs) and cardiovascular disease (CVD) remain controversial. To clarify associations between APOL1 and CVD, a total of 2568 African American Systolic Blood Pressure Intervention Trial (SPRINT) participants were a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freedman, Barry I., Rocco, Michael V., Bates, Jeffrey T., Chonchol, Michel, Hawfield, Amret T., Lash, James P., Papademetriou, Vasilios, Sedor, John R., Servilla, Karen, Kimmel, Paul L., Wall, Barry M., Pajewski, Nicholas M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527675/ https://www.ncbi.nlm.nih.gov/pubmed/28758155 http://dx.doi.org/10.1016/j.ekir.2017.03.008

Ejemplares similares

Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial
por: Langefeld, Carl D., et al.
Publicado: (2014)

Should kidney donors be genotyped for APOL1 risk alleles?
por: Freedman, Barry I., et al.
Publicado: (2015)

Lack of APOL1 in proximal tubules of normal human kidneys and proteinuric APOL1 transgenic mouse kidneys
por: Blessing, Natalya A., et al.
Publicado: (2021)

Association of preeclampsia with infant APOL1 genotype in African Americans
por: Miller, Anna K., et al.
Publicado: (2020)

JC polyoma virus interacts with APOL1 in African Americans with non-diabetic nephropathy
por: Divers, Jasmin, et al.
Publicado: (2013)

Arterial stiffness and kidney disease progression in the systolic blood pressure intervention trial
por: Nowak, Kristen L., et al.
Publicado: (2020)

Pulse wave velocity and central aortic pressure in systolic blood pressure intervention trial participants
por: Supiano, Mark A., et al.
Publicado: (2018)

Response to Comment on Chan et al. FGF23 Concentration and APOL1 Genotype Are Novel Predictors of Mortality in African Americans With Type 2 Diabetes. Diabetes Care 2018;41:178–186
por: Divers, Jasmin, et al.
Publicado: (2018)

APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans
por: Bentley, Amy R., et al.
Publicado: (2015)

Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial
por: Still, Carolyn H, et al.
Publicado: (2018)

APOL1 Kidney-Risk Variants Induce Mitochondrial Fission
por: Ma, Lijun, et al.
Publicado: (2020)

Intensive Blood Pressure Control, APOL1 Genotype, and Kidney Outcomes in Individuals With Type 2 Diabetes: A Post Hoc Analysis of the Action to Control Cardiovascular Risk in Diabetes-Blood Pressure (ACCORD-BP) Trial
por: Dinh, Alex, et al.
Publicado: (2021)

APOL1-G0 protects podocytes in a mouse model of HIV-associated nephropathy
por: Bruggeman, Leslie A., et al.
Publicado: (2019)

Effect of APOL1 disease risk variants on APOL1 gene product
por: Haque, Shabirul, et al.
Publicado: (2017)

Effects of renin‐angiotensin blockade and APOL1 on kidney function in sickle cell disease
por: Han, Jin, et al.
Publicado: (2021)

Association of APOL1 variants with mild kidney disease in first-degree relatives of African American patients with non-diabetic end stage renal disease
por: Freedman, Barry I., et al.
Publicado: (2012)

APOL1 Risk Variants and Subclinical Cardiovascular Disease in Incident Hemodialysis Patients
por: Chen, Teresa K., et al.
Publicado: (2020)

Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults
por: Freeberg, Kaitlin A., et al.
Publicado: (2022)

APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes
por: Freedman, Barry I., et al.
Publicado: (2014)

Marsyas und apoll : fur flöte ünd klavier /
por: Muench, Gerhart, 1907-1988
Publicado: (1991)

APOL1 polymorphism modulates sphingolipid profile of human podocytes
por: Valsecchi, Manuela, et al.
Publicado: (2020)

APOL1 genotypes: Do they contribute to ethnicity-associated biological health inequalities in pregnancy?
por: Smith, Priscilla, et al.
Publicado: (2021)

APOL1 Genetic Testing in Patients With Recent African Ancestry and Hypertension: A Pilot Study of Attitudes and Perceptions
por: Lentine, Krista L., et al.
Publicado: (2022)

Transcription and translation of APOL1 variants
por: Ejaz, Samina
Publicado: (2017)

The metabolic effects of APOL1 in humans
por: Adeva-Andany, María M., et al.
Publicado: (2023)

FGF23 Concentration and APOL1 Genotype Are Novel Predictors of Mortality in African Americans With Type 2 Diabetes
por: Chan, Gary C., et al.
Publicado: (2018)

APOL1 Null Alleles from a Rural Village in India Do Not Correlate with Glomerulosclerosis
por: Johnstone, Duncan B., et al.
Publicado: (2012)

APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin
por: Uzureau, Sophie, et al.
Publicado: (2020)

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale
por: Freedman, Barry I., et al.
Publicado: (2019)

Copy Number Variation at the APOL1 Locus
por: Ruchi, Rupam, et al.
Publicado: (2015)

A Focus on APOL1 and Kidney Disease
por: Nestor, Jordan, et al.
Publicado: (2019)

APOL1-Associated Kidney Disease in Brazil
por: Riella, Cristian, et al.
Publicado: (2019)

APOL1, Acid Load, and CKD Progression
por: Pike, Mindy, et al.
Publicado: (2019)

Lessons From APOL1 Animal Models
por: Yoshida, Teruhiko, et al.
Publicado: (2021)

Differential Effects of MYH9 and APOL1 Risk Variants on FRMD3 Association with Diabetic ESRD in African Americans
por: Freedman, Barry I., et al.
Publicado: (2011)

APOL1 renal risk variants promote cholesterol accumulation in tissues and cultured macrophages from APOL1 transgenic mice
por: Ryu, Jung-Hwa, et al.
Publicado: (2019)

Recessive, gain-of-function toxicity in an APOL1 BAC transgenic mouse model mirrors human APOL1 kidney disease
por: McCarthy, Gizelle M., et al.
Publicado: (2021)

APOL1 and APOL1-Associated Kidney Disease: A Common Disease, an Unusual Disease Gene − Proceedings of the Henry Shavelle Professorship
por: Pollak, Martin R., et al.
Publicado: (2023)

APOL1 Toxin, Innate Immunity and Kidney Injury
por: Limou, Sophie, et al.
Publicado: (2015)

APOL1 variants contribute to racial disparity in sepsis
por: Bird, Lucy
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bd47u2qnoogag84t3drq2bgo8u